These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 24243574)

  • 1. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
    Michl P
    Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug interactions: the importance of looking inside cancer cells.
    Clark JW
    Cancer Discov; 2012 Mar; 2(3):208-10. PubMed ID: 22585991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
    Frese KK; Neesse A; Cook N; Bapiro TE; Lolkema MP; Jodrell DI; Tuveson DA
    Cancer Discov; 2012 Mar; 2(3):260-269. PubMed ID: 22585996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
    Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
    Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
    Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling.
    Cowan RW; Maitra A; Rhim AD
    Gastroenterology; 2015 Dec; 149(7):1685-8. PubMed ID: 26526714
    [No Abstract]   [Full Text] [Related]  

  • 7. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
    Parasido E; Avetian GS; Naeem A; Graham G; Pishvaian M; Glasgow E; Mudambi S; Lee Y; Ihemelandu C; Choudhry M; Peran I; Banerjee PP; Avantaggiati ML; Bryant K; Baldelli E; Pierobon M; Liotta L; Petricoin E; Fricke ST; Sebastian A; Cozzitorto J; Loots GG; Kumar D; Byers S; Londin E; DiFeo A; Narla G; Winter J; Brody JR; Rodriguez O; Albanese C
    Mol Cancer Res; 2019 Sep; 17(9):1815-1827. PubMed ID: 31164413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines.
    Braun LM; Lagies S; Guenzle J; Fichtner-Feigl S; Wittel UA; Kammerer B
    Cells; 2020 May; 9(5):. PubMed ID: 32438599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Von Hoff DD; Goldstein D; Renschler MF
    N Engl J Med; 2014 Jan; 370(5):479-80. PubMed ID: 24476438
    [No Abstract]   [Full Text] [Related]  

  • 10. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Saltz LB; Bach PB
    N Engl J Med; 2014 Jan; 370(5):478. PubMed ID: 24476439
    [No Abstract]   [Full Text] [Related]  

  • 11. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Sahoo RK; Kumar L
    N Engl J Med; 2014 Jan; 370(5):478-9. PubMed ID: 24476440
    [No Abstract]   [Full Text] [Related]  

  • 12. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action.
    Al-Batran SE; Geissler M; Seufferlein T; Oettle H
    Oncol Res Treat; 2014; 37(3):128-34. PubMed ID: 24685917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of hypoxia-induced CAV1 autophagic degradation enhances nanoalbumin-paclitaxel transcytosis and improves therapeutic activity in pancreatic cancer.
    Bai X; Xiong J; Li L; Yu C; Sun C
    Eur J Pharmacol; 2024 Apr; 969():176431. PubMed ID: 38395374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New option for the initial management of metastatic pancreatic cancer?
    Abbruzzese JL; Hess KR
    J Clin Oncol; 2014 Aug; 32(23):2405-7. PubMed ID: 24982449
    [No Abstract]   [Full Text] [Related]  

  • 15. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
    Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
    Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
    [No Abstract]   [Full Text] [Related]  

  • 16. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
    Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
    Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes.
    Kolyvas E; Rudloff M; Poruchynsky M; Landsman R; Hollevoet K; Venzon D; Alewine C
    Oncotarget; 2017 Feb; 8(6):9189-9199. PubMed ID: 27999204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure.
    Chauhan VP; Boucher Y; Ferrone CR; Roberge S; Martin JD; Stylianopoulos T; Bardeesy N; DePinho RA; Padera TP; Munn LL; Jain RK
    Cancer Cell; 2014 Jul; 26(1):14-5. PubMed ID: 25026209
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.